(E)-3-(2-methylpyridin-3-yl)acrylic acid | 118419-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (E)-3-(2-methylpyridin-3-yl)acrylic acid
• 英文别名: 3-(2-Methyl-3-pyridyl)acrylic acid；3t-(2-methyl-[3]pyridyl)-acrylic acid；3t-(2-Methyl-[3]pyridyl)-acrylsaeure；3-(2-methyl-pyridin-3-yl)-acrylic acid；3-(2-methyl-3-pyridyl)-acrylic acid；(E)-3-(2-methylpyridin-3-yl)prop-2-enoic acid
• CAS: 118419-95-7
• 化学式: C₉H₉NO₂
• 分子量: 163.176
• InChiKey: VFALXECYZPKXAM-SNAWJCMRSA-N

物化性质

• 熔点：
  218-219 °C
• 沸点：
  300.6±27.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(2-methylpyridin-3-yl)acrylic acid 在 水 、 铂 作用下， 生成 3-吡啶-2-基丙酸
  参考文献：
  名称：

  Dornow; Bormann, Chemische Berichte, 1949, vol. 82, p. 216

  摘要：

  DOI：
• 作为产物：
  描述：

  3-羟甲基-2-甲基吡啶 在 哌啶 、 吡啶 、 chromium(VI) oxide 作用下， 以 吡啶 为溶剂， 反应 10.0h， 生成 (E)-3-(2-methylpyridin-3-yl)acrylic acid
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012

文献信息

• Tetrazole amide derivatives of heterocyclic alkenyl acids and their use as antiallergic substances
  申请人：VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA

  公开号：EP0384450A1

  公开（公告）日：1990-08-29

  Tetrazole amide derivatives of heterocyclic alkenyl acids, of general formula (I): in which Y = NH, O or S when m = 1; Y = N when m = 2; m = 1 or 2; l = 0 or 4; R = H, C₁₋₄ alkyl, Cl, Br, CF₃, CH₂OCOCH₃, or OCH₂-Ph; R₁ = H, alkaline metal or alkaline earth metal; the double bond of the alkenyl chain being of trans or cis configuration and the possible benzene ring being unsubstituted or substituted. Said derivatives possess high antiallergic activity.

  杂环烯烃酸的四唑酰胺衍生物，一般式（I）如下：其中Y = NH、O或S，当m = 1 时；Y = N，当m = 2 时；m = 1 或 2；l = 0 或 4；R = H、C₁₋₄烷基、Cl、Br、CF₃、CH₂OCOCH₃或OCH₂-Ph；R₁ = H、碱金属或碱土金属；烯烃链的双键为顺式或反式构型，可能的苯环未取代或取代。这些衍生物具有很高的抗过敏活性。
• Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160221994A1

  公开（公告）日：2016-08-04

  The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  本发明通常涉及取代的2,3-二氢苯并呋喃基化合物，更具体地涉及由结构式（I）表示的化合物，或其药学上可接受的盐，在此变量的定义和描述中。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组合物，例如在治疗癌症（例如曼托细胞淋巴瘤）和其他疾病和障碍中。
• [EN] MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS MULTICYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2015042414A8

  公开（公告）日：2015-08-06
• Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP0210782B1

  公开（公告）日：1991-04-17
• Multicyclic Compounds And Methods Of Using Same
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20170096417A1

  公开（公告）日：2017-04-06

  The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).